Testing cadonilimab and lenvatinib before liver cancer surgery
Part of Cancer clinical trials.
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma (HCC).
- Your cancer is at a stage where surgery can't be done now, either because it's advanced (Stage C) but hasn't spread to lymph nodes or distant organs, or it's Stage B but not removable by surgery.
- You have at least one tumor that can be measured on a scan (like a CT scan).
- You have not had any previous cancer treatment (like chemo, targeted pills, or procedures like embolization or ablation).
- Your liver is working relatively well (Child-Pugh score less than 7) and you have no fluid buildup in your belly (ascites) or recent bleeding from your stomach.
- Your overall health is good enough that you can perform daily activities (ECOG score 0 or 1), and your blood counts and organ function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Hear when a new Cadonilimab and Lenvatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.